Sagimet Biosciences (STU:0O2) Price-to-Owner-Earnings: (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:0O2 Sagimet Biosciences Inc STU:0O2
18 GF Score
Price €6.16
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Sagimet Biosciences Price-to-Owner-Earnings?

As of today (2026-08-02), Sagimet Biosciences's share price is €6.16. Sagimet Biosciences does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Sagimet Biosciences's Price-to-Owner-Earnings or its related term are showing as below:


STU:0O2's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 24.95
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2026-08-02), Sagimet Biosciences's share price is €6.16. Sagimet Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.15. Therefore, Sagimet Biosciences's PE Ratio (TTM) for today is At Loss.

As of today (2026-08-02), Sagimet Biosciences's share price is €6.16. Sagimet Biosciences's EPS without NRI for the trailing twelve months (TTM) ended in was €-1.15. Therefore, Sagimet Biosciences's PE Ratio without NRI for today is At Loss.


Sagimet Biosciences  (STU:0O2) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Sagimet Biosciences Price-to-Owner-Earnings Related Terms


Sagimet Biosciences Price-to-Owner-Earnings Historical Data

* Premium members only.

The historical data trend for Sagimet Biosciences's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sagimet Biosciences Price-to-Owner-Earnings Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Price-to-Owner-Earnings
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Sagimet Biosciences Quarterly Data
Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:0O2 vs CABA, OVID, QTTB: Price-to-Owner-Earnings Comparison

For the Biotechnology subindustry, Sagimet Biosciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sagimet Biosciences Price-to-Owner-Earnings vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Sagimet Biosciences's Price-to-Owner-Earnings falls into.


STU:0O2
18GF Score
Sagimet Biosciences Inc STU:0O2
Price-to-Owner-Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sagimet Biosciences Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Sagimet Biosciences's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=6.16/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sagimet Biosciences Business Description

Other Exchanges SGMT:USA
Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
18GF Score

Get the complete analysis for STU:0O2

Price-to-Owner-Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.16
Price